FDA has recently approved olaparib to be used in patients with metastatic breast cancer with an inherited BRCA mutation.
Highlights:
The
U.S. Food and Drug Administration (FDA) has approved the expansion of the
indications of the anti-cancer drug olaparib. Olaparib can
now be used to treat patients with certain breast cancers that have spread and
where the tumors are caused by a specifically inherited genetic mutation called
BRCA mutation. Olaparib is the first drug in its class, a PARP protein inhibitor, to
be approved to treat breast cancer and specifically for such an indication.
Olaparib has been specifically indicated
for abnormal inherited (germline) breast cancer susceptibility (BRCA) gene, human epidermal growth factor
receptor 2 (HER2)-negative breast cancer that has spread to other parts of the
body (metastatic). - The US FDA has endorsed olaparib suitable to treat certain breast cancers that have spread to other parts of the body and have a specific inherited gene mutation (mutated-BRCA).
- Olaparib is currently used to treat advanced ovarian cancers due to an inherited BRCA gene mutation.
- In a recent clinical trial in BRCA positive metastatic breast cancer, olaparib provided a more safe and effective treatment option than standard chemotherapy.
These patients should have received anti-cancer or chemotherapy drugs, either before or after cancer has spread. If the patients have hormone receptor (HR)-positive breast cancer then they should have either been treated with a prior hormonal (endocrine) therapy or be considered inappropriate for endocrine treatment.
Patients have to undergo an FDA-approved genetic test called the BRACAnalysis CDx to be eligible for treatment with olaparib. To suit the current new indication, the FDA has also expanded the approval of the BRACAnalysis CDx to include detection of BRCA mutations in blood samples from patients with breast cancer.
The approval follows the positive results of the Phase 3 OlympiAD Clinical Trial that evaluated the efficacy and safety of olaparib:
Patients (302 in number) with HER2-negative metastatic breast cancer with an inherited BRCA mutation and who had received one or two previous chemotherapy regimens were eligible for the clinical trial. They were randomly assigned (in a ratio of 2:1) to receive olaparib tablets (300 mg twice daily) or standard therapy (capecitabine, eribulin, or vinorelbine in 21-day cycles).
The primary endpoint of the study was progression-free survival or PFS which is the length of time after the treatment that the tumors do not grow significantly or do not get worse.
Breast Cancer - Causes, Risks, Symptoms, Diagnosis, Staging, Treatment, Prevention & Prognosis
Breast cancer is a cancer that affects the breasts or mammary glands. Early detection and lifestyle changes help in controlling breast cancer.
Breast cancer is a cancer that affects the breasts or mammary glands. Early detection and lifestyle changes help in controlling breast cancer.
‘Olaparib has shown promise as an anti-cancer therapy in patients with HER-2 negative metastatic breast cancer and a germline BRCA mutation.’
Advertisement
Results of the Study
- The median PFS was significantly longer (7 months in the olaparib group) compared to 4.2 months for patients in the standard-therapy group.
- Patients in the olaparib group had a better response rate (59.9%) compared with 28.8% in the standard-therapy group.
- Olaparib also proved to be a safer treatment option (the rates of grade 3 or higher adverse events was 36.6% with olaparib, compared with 50.5% standard therapy drugs). In addition, lesser patients had to discontinue due to the toxic effects olaparib during the trial.
- Based on this study, it appears that olaparib provides a safer and more effective treatment option than standard chemotherapy for patients with HER2-negative metastatic breast cancer and an inherited BRCA mutation.
In the US, olaparib is already in the market for the treatment of women who have advanced ovarian cancer due to a certain type of mutated inherited BRCA gene and who have also received three or more prior lines of chemotherapy. Other indications for which olaparib is prescribed are epithelial ovarian, fallopian tube or primary peritoneal cancers that have recurred.
“This class of drugs has been used to treat advanced, BRCA-mutated ovarian cancer and has now shown efficacy in treating certain types of BRCA-mutated breast cancer,” said Richard Pazdur, M.D., director of the FDA’s Oncology Center of Excellence and acting director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research. “This approval demonstrates the current paradigm of developing drugs that target the underlying genetic causes of a cancer, often across cancer types.”
Advertisement
Interesting Facts About Breast Cancer
Breast cancer is the most commonly diagnosed cancer in women and in 2020 and nearly 2.3 million breast cancers were diagnosed globally.
Breast cancer is the most commonly diagnosed cancer in women and in 2020 and nearly 2.3 million breast cancers were diagnosed globally.
About PARP and BRCA
DNA or deoxyribose nucleic acid contains the genetic instructions used by most living organisms to grow, develop, function and reproduce. It is thus a vital substance found in all the cells of the body. By nature, one strand or both strands of DNA can break or get damaged and when that happens, the DNA undergoes a repair mechanism.Both PARP and BRCA are proteins that are involved in repairing damaged DNA. PARP or poly (ADP-ribose) polymerase proteins are enzymes that repair DNA when one strand breaks.
BRCA proteins repair DNA when both strands break. Thus, BRCA genes normally work to prevent tumor development. When BRCA genes get mutated (mutated-BRCA), the respective proteins function abnormally and errors occur in the DNA repair. This may lead to certain cancers, including breast cancers.
Olaparib, being a PARP inhibitor, works by inhibiting the activity of PARP enzymes, in other words, stalls the repair of damaged DNA.
With the BRCA genes already mutated in cancerous cells, blocking PARP enzyme further prevents DNA repair, resulting in a buildup of damaged DNA, leading to cell death and possibly a slow-down or stoppage of tumor growth.
Advertisement
PARP Inhibitors Could Play a Role in Breast Cancer Treatment
BRCA1 And BRCA2 Are Human Genes That Produce Tumor Suppressor Proteins. These Proteins Help Repair Damaged DNA.
BRCA1 And BRCA2 Are Human Genes That Produce Tumor Suppressor Proteins. These Proteins Help Repair Damaged DNA.
About Breast Cancer
Breast cancer is cancer that starts in the breast tissue. It is the most common form of cancer in women, affecting 1 in 8 women. It can affect men too. BRCA1 and BRCA2 genes are two different genes (BRCA is BReast CAncer gene) which when mutated can increase the risk of female breast and ovarian cancers. Around 20-25 percent of patients with hereditary breast cancers have a BRCA mutation in their genes.References:
- FDA approves first treatment for breast cancer with a certain inherited genetic mutation - (https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm592347.htm)
- Mark Robson, M.D., Seock-Ah Im, M.D., Ph.D., El bieta Senkus, M.D., Ph.D., Binghe Xu, M.D., Ph.D., Susan M. Domchek, M.D., Norikazu Masuda, M.D., Ph.D., Suzette Delaloge, M.D., Wei Li, M.D., Nadine Tung, M.D., Anne Armstrong, M.D., Ph.D., Wenting Wu, Ph.D., Carsten Goessl, M.D., Sarah Runswick, Ph.D., and Pierfranco Conte, M.D. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. N Engl J Med 2017; 377:523-533August 10, 2017 DOI: 10.1056/NEJMoa1706450
Success in Tumor Response Rate With Olaparib
Overall tumor response rate of 26 percent is seen with Olaparib, an experimental twice-daily oral cancer drug, in several advanced cancers associated with BRCA1 and BRCA2 mutations.
Overall tumor response rate of 26 percent is seen with Olaparib, an experimental twice-daily oral cancer drug, in several advanced cancers associated with BRCA1 and BRCA2 mutations.
